Editorial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. Jan 19, 2025; 15(1): 100297
Published online Jan 19, 2025. doi: 10.5498/wjp.v15.i1.100297
Interleukin-6 in epilepsy and its neuropsychiatric comorbidities: How to bridge the gap
Xiao-Man Chen, Shuo Zhang, Shi-Qi Gao, Michael Xu
Xiao-Man Chen, Shuo Zhang, Department of Neurology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Shi-Qi Gao, Department of Rehabilitation, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110004, Liaoning Province, China
Michael Xu, International Education School, China Medical University, Shenyang 110004, Liaoning Province, China
Author contributions: Zhang S and Chen XM conceived and designed the editorial, wrote the paper; Zhang S and Xu M reviewed and edited the manuscript; Chen XM, Zhang S, Gao SQ and Xu M revised the paper; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shuo Zhang, MD, PhD, Assistant Professor, Department of Neurology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang 110004, Liaoning Province, China. flybird31025@163.com
Received: August 12, 2024
Revised: October 31, 2024
Accepted: November 21, 2024
Published online: January 19, 2025
Processing time: 127 Days and 9.5 Hours
Core Tip

Core Tip: Interleukin (IL)-6 homeostasis is crucial in the pathophysiology of epilepsy and its associated neuropsychiatric comorbidities, suggesting its potential utility as a biomarker for disease activity. Therapeutic strategies aimed at inhibiting IL-6 signaling through receptor blockade represent a novel and promising approach for treating epilepsy and its neuropsychiatric manifestations. Elucidating the mechanisms by which IL-6 modulates epilepsy and its neuropsychiatric comorbidities can provide valuable insights into potential therapeutic targets, thereby enhancing patient outcomes.